Introduction:
Minaris Regenerative Medicine plans to invest US$64.5 million to open new manufacturing facilities in Asia and Europe. This expansion increases the cell and gene manufacturing capabilities.
Features:
The project laid with an investment of US$64.5 million will expand the manufacturing sites of both Europe and Asia.
European Facility Expansion:
The European facility constructed with an US$40.7 million will cover an area of 6,650 sqm. This additional investment doubles the size of the existing capacity in Europe by further adding clean rooms, quality control laboratories, warehousing, cryo-storage, and office space.
European new state of the art facility will be constructed adjacent to the existing site in Ottobrunn near Munich.
The new manufacturing facility will be committed to clinical and commercial manufacturing as well as development services for cell and gene therapies.
It is expected that the new facility will open in 2023.
Asian site expansion:
The investment of US$23.8 million is planned to launch a center for cancer immunotherapy and somatic stem cells. The new facility consisting of an additional 4,000 sqm will be opened near to the current facility.
This expansion is planned to double the capacity of regenerative medicine for commercial manufacturing.
The new facility is set to begin its operations in October 2022.
Specifications:
| Name | Minaris Regenerative Medicine |
| Type | Expansion of Manufacturing Facility in Europe and Asia |
| Budget | US$64.5 million |
| Year | European Site Expansion (2023), Asian site expansion (2022) |
